Dynavax taps Yu to head vaccine research; plus CFO moves at Lilly, Gemini, Caribou and Lyell

Dong Yu joined vaccine developer  Dynavax Technologies Corp. (NASDAQ:DVAX) as SVP of vaccine research. Yu was previously head of preclinical R&D U.S. at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK).

Eli Lilly and Co. (NYSE:LLY) said SVP and CFO Josh Smiley resigned after an investigation of allegations that he had an inappropriate personal relationship with an employee. The pharma promoted Anat Ashkenazi to succeed Smiley; she had been SVP, controller and CFO of Lilly Research Laboratories...